Former ASML CEO says US-China Chip Fight Will Continue

Peter Wennink, President and CEO of Dutch chip machine maker ASML presents his company's Q4 results, in Veldhoven, Netherlands January 24, 2024. REUTERS/Piroschka van de Wouw/File Photo Purchase Licensing Rights
Peter Wennink, President and CEO of Dutch chip machine maker ASML presents his company's Q4 results, in Veldhoven, Netherlands January 24, 2024. REUTERS/Piroschka van de Wouw/File Photo Purchase Licensing Rights
TT

Former ASML CEO says US-China Chip Fight Will Continue

Peter Wennink, President and CEO of Dutch chip machine maker ASML presents his company's Q4 results, in Veldhoven, Netherlands January 24, 2024. REUTERS/Piroschka van de Wouw/File Photo Purchase Licensing Rights
Peter Wennink, President and CEO of Dutch chip machine maker ASML presents his company's Q4 results, in Veldhoven, Netherlands January 24, 2024. REUTERS/Piroschka van de Wouw/File Photo Purchase Licensing Rights

The recently retired CEO of semiconductor equipment maker ASML said in an interview with Dutch radio station BNR on Saturday that US-China disputes over computer chips are ideological and not based on facts, and they are set to continue.

Wennink left in April after a ten year term at the helm of ASML that saw it become Europe's largest technology firm. Since 2018, the US has imposed increasing restrictions on what tools the company can export to China, its second-largest market after Taiwan, citing security concerns. According to Reuters, most recently the US has sought to keep the company from servicing equipment already sold to Chinese customers.

"These kind of discussions are not being conducted on the basis of facts or content or numbers or data but on the basis of ideology," Wennink said.

"You can think whatever you want about that, but we're a business where the interests of your stakeholders have to be managed in balance ... If ideology cuts straight through that, I have problems with that."

He said the company has had customers and staff in China for 30 years "so you also have obligations".

As part of seeking to strike a balance, Wennink said he had lobbied where possible to prevent export restrictions from becoming too tight, and at the same time he had complained to high-ranking Chinese politicians when he felt the company's intellectual property wasn't being respected.

"I think in Washington, maybe they sometimes thought, that Mr. Wennink, maybe he's a friend of China," he said.

"No. I'm a friend to my customers, to my suppliers, to my employees, to my shareholders."

He forecast that given geopolitical interests are at stake, the chip war could take decades to play out.

"This is going to go on for a while," he said.

 

 

 

 

 



Intuitive Surgical Results Beat on Growing Demand for Surgical Robots

Representation photo: Employees work at the office of humanoid robots developer Ex-Robots in Dalian, Liaoning province, China June 6, 2024. REUTERS/Florence Lo
Representation photo: Employees work at the office of humanoid robots developer Ex-Robots in Dalian, Liaoning province, China June 6, 2024. REUTERS/Florence Lo
TT

Intuitive Surgical Results Beat on Growing Demand for Surgical Robots

Representation photo: Employees work at the office of humanoid robots developer Ex-Robots in Dalian, Liaoning province, China June 6, 2024. REUTERS/Florence Lo
Representation photo: Employees work at the office of humanoid robots developer Ex-Robots in Dalian, Liaoning province, China June 6, 2024. REUTERS/Florence Lo

Intuitive Surgical on Thursday beat estimates for second-quarter profit and revenue on growing demand for its surgical robots used in minimally invasive procedures, sending its shares up 6.7% after the bell.
Investor expectations around medical device makers have grown lately on hopes of elevated demand for surgical procedures as people, especially older adults, opt for medical procedures deferred during the pandemic, Reuters said.
On an adjusted basis, Intuitive earned $1.78 per share for the quarter ended June 30, beating analysts' estimates of $1.54 per share, according to LSEG data.
The company reported quarterly revenue of $2.01 billion, compared with analysts' estimates of $1.97 billion.
The rise in revenue was driven in part by growth in the procedure volume from the company's surgical robots called da Vinci. Worldwide da Vinci procedure volumes rose about 17%, from a year ago, the company said.
Industry bellwether Johnson & Johnson on Wednesday posted a 2.2% rise in second quarter sales at its medical technology business, but fell short of analysts' estimates.
Larger peer Abbott Laboratories also raised its annual profit forecast, helped by double-digit growth in sales of its glucose monitors and strong demand for heart devices.